Managing the IBD Patient: Change in Diagnosis – Transformation from UC to Crohn’s Disease Evaluation (ID: i754) Question Title * 1. How many years have you been in practice? >21 11-20 1-10 <1 Question Title * 2. How many patients with IBD do you see each week? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 3. Please select the option that best describes your practice: Academic Clinician Community Clinician Other (please specify) Question Title * 4. Of the patients you will see in the next week, about how many will benefit from the information you learned today? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 5. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply. Be better able to recognize treatment non-responders Be better able to switch therapy Be better able to address perianal fistula Be better able to optimize use of tofacitinib Be better able to implement guideline directed treatment strategies Question Title * 6. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes Question Title * 7. After participating in today’s activity, I am now able to: Strongly agree Agree Neutral Disagree Strongly disagree Outline current approaches and guideline-directed strategies for the management of IBD Outline current approaches and guideline-directed strategies for the management of IBD Strongly agree Outline current approaches and guideline-directed strategies for the management of IBD Agree Outline current approaches and guideline-directed strategies for the management of IBD Neutral Outline current approaches and guideline-directed strategies for the management of IBD Disagree Outline current approaches and guideline-directed strategies for the management of IBD Strongly disagree Evaluate pivotal clinical trial data and real-world studies of new and emerging agents for the treatment of IBD Evaluate pivotal clinical trial data and real-world studies of new and emerging agents for the treatment of IBD Strongly agree Evaluate pivotal clinical trial data and real-world studies of new and emerging agents for the treatment of IBD Agree Evaluate pivotal clinical trial data and real-world studies of new and emerging agents for the treatment of IBD Neutral Evaluate pivotal clinical trial data and real-world studies of new and emerging agents for the treatment of IBD Disagree Evaluate pivotal clinical trial data and real-world studies of new and emerging agents for the treatment of IBD Strongly disagree Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD Strongly agree Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD Agree Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD Neutral Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD Disagree Analyze challenging patient cases to identify alternate clinical approaches and enhance patient outcomes for IBD Strongly disagree Question Title * 8. The content presented: Strongly agree Agree Neutral Disagree Strongly disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly disagree Addressed my most pressing questions Addressed my most pressing questions Strongly agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly disagree Question Title * 9. This activity was free from commercial bias. Yes No Question Title * 10. If you indicated that you perceived commercial bias or influence, please describe: Question Title * 11. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 12. What barriers do you see to making changes in your practice? a. Lack of knowledge regarding evidence-based strategies b. Lack of convincing evidence to warrant change c. Lack of time/resources to consider change d. Insurance, reimbursement, or legal issues e. Conflicting guidelines and/or evidence f. Patient compliance and/or patient resource barriers Other (please specify) Question Title * 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities: Done